Methylene Blue

Overview

Methylene blue (methylthioninium chloride) is a synthetic phenothiazine redox dye and a small molecule — it is not a peptide. It has been used for over a century as a biological stain (hence names like Basic Blue 9, Swiss blue, and the colour index code CI 52015). It appears on this peptide wiki for one reason: it is frequently discussed and stacked alongside peptides in the nootropic and longevity community, not because it belongs to the same chemical family.

Two very different stories sit inside this one molecule, and it is important to keep them separate:

1. An approved medicine, for one specific job. Methylene blue is a genuinely approved drug — FDA-approved (ProvayBlue, Provepharm; accelerated approval 2016) and EMA-approved (Proveblue; 2011) — as an intravenous treatment for acquired, drug- and chemical-induced methemoglobinemia. In that setting it accelerates the enzymatic reduction of methemoglobin (Fe3+) back to functional hemoglobin (Fe2+), restoring the blood's ability to carry oxygen [Human — approved mechanism].

2. A popular "mitochondrial" nootropic, on a much weaker footing. Its biohacking popularity rests on a separate, largely preclinical rationale: at low concentrations it may act as an alternative mitochondrial electron carrier [In vitro / Animal]. This use is off-label and not an approved indication.

Chemistry and structure

The reported molecular weight refers to the anhydrous chloride salt. Because methylene blue is commonly supplied as a hydrate, the exact molecular weight depends on the salt and hydrate form.

Mechanism of action

Methylene blue is fundamentally an oxidation-reduction (electron-cycling) agent that shifts between an oxidized (blue) form and a reduced, colourless leuco form (MB ↔ MBH2).

• Approved mechanism — methemoglobinemia [Human]. It accelerates the conversion of methemoglobin (Fe3+) to hemoglobin (Fe2+) via NADPH-methemoglobin reductase, restoring oxygen-carrying capacity. This is the mechanism underlying its FDA/EMA approval. (Source: FDA ProvayBlue label; EMA Proveblue EPAR.)
• Alternative mitochondrial electron carrier [In vitro]. In cell and biochemical models, the reduced (leuco) form is proposed to donate electrons to cytochrome c / complex IV, effectively bypassing inhibited complexes I and III, while cycling MB ↔ MBH2 as a regenerable redox shuttle. (Source: Yang et al., Progress in Neurobiology 2017, PMC4871783.)
• Reduced electron leak / antioxidant behaviour [In vitro]. By smoothing electron flow it may attenuate reactive-oxygen-species (ROS) overproduction, functioning as a regenerable mitochondrial antioxidant distinct from simple free-radical scavengers. (Sources: PMC4871783; PMC3485214.)
• Neuroprotection in rodent models [Animal]. These mechanisms underlie neuroprotective effects reported in rodent models of Alzheimer's, Parkinson's, and Huntington's disease — animal models, not human efficacy. (Source: PMC3485214.)
• Monoamine oxidase inhibition [Human]. Methylene blue is a potent MAO-A/MAO-B inhibitor, which is the biochemical basis for its serotonin-syndrome risk with serotonergic drugs. (Source: Ramsay et al., Br J Pharmacol 2007/2008, PMID 18451123; FDA label warning.)
• Acute cognitive modulation [Human — small]. A single low oral dose modulated task-related fMRI activity and enhanced short-term memory retrieval in healthy adults — a single-dose, N=26 finding, not chronic-benefit evidence. (Source: Rodriguez et al., Radiology 2016, PMID 27351678.)

Research and evidence

Human evidence, honestly stated. The strong, well-established human evidence is confined to the approved indication — reversing methemoglobinemia. For cognition, the most-cited human study (Rodriguez et al., Radiology 2016) was a single-dose, randomized, placebo-controlled fMRI study in only 26 healthy adults; it found increased task-related brain activity and a ~7% improvement in memory retrieval after ~280 mg (~4 mg/kg) oral MB [Human — small, acute, healthy volunteers]. That is a real but limited result: single dose, tiny sample, no durable-benefit claim. Separately, a related purified methylthioninium / tau-aggregation inhibitor (LMTM / TRx0237) failed its primary endpoints in large phase 3 Alzheimer's trials [Human], with only a contested monotherapy-subgroup signal. The mitochondrial and neuroprotective story remains in-vitro and animal [In vitro / Animal].

Malaria — the first synthetic antimalarial, and modern African trials

Long before the nootropic and "mitochondrial" marketing, methylene blue was a medicine of firsts. Synthesised as a dye by Heinrich Caro in 1876, it became the first fully synthetic drug used in medicine, and in 1891 Guttmann and Ehrlich used it to cure two malaria patients — the first synthetic antimalarial ever reported. Its phenothiazine core later seeded whole drug classes (antipsychotics, antihistamines).

That malaria story is not just history. Methylene blue has been revisited in modern randomized trials in West Africa, where its distinctive property is killing the transmissible (gametocyte) stage of Plasmodium falciparum:

• [Human] In Burkina Faso, adding methylene blue to artemisinin-based combinations sharply cut gametocyte carriage — one randomized trial reported day-7 gametocyte prevalence of 1.2% vs 8.9% (microscopy) with versus without methylene blue — a strong gametocytocidal effect in children with uncomplicated malaria (J. Infect. Dis. 2015).
• [Human] A phase-2 randomized trial in Mali (Dicko et al., Lancet Infect. Dis. 2018) tested methylene blue and primaquine specifically to block onward transmission of P. falciparum — a public-health goal (shrinking the infectious reservoir), distinct from merely curing the patient.

A serious, population-relevant safety caveat. Methylene blue requires G6PD to function and is contraindicated in G6PD deficiency, where it can trigger haemolysis and paradoxically worsen methaemoglobinaemia. G6PD deficiency is common in malaria-endemic populations — which is exactly why it is a live clinical issue in these African trials, and a caution the wellness-market framing usually omits.

Honest scope: this is real, active tropical-medicine research — genuine RCTs in African children — a world away from the "brain-boosting" positioning, and a reminder that methylene blue is a potent redox-active drug with real contraindications, not a benign supplement.

Status and regulation

• Approved (FDA, 2016): ProvayBlue (methylene blue injection, Provepharm) received accelerated approval for the treatment of pediatric and adult acquired methemoglobinemia.
• Approved (EMA, 2011): Methylthioninium chloride Proveblue for acute symptomatic treatment of drug- and chemical-induced methaemoglobinaemia in adults, children, and adolescents.
• Established off-label medical uses: e.g., ifosfamide encephalopathy, vasoplegic syndrome, and surgical staining.
• Not an approved indication: low-dose cognitive/nootropic and anti-aging use is off-label.

Methylene blue is also sold as a research reagent and as consumer "pharmaceutical-grade" solutions; purity versus industrial-grade material (with heavy-metal contamination risk) is not verifiable from these sources.

Safety

• Serotonin syndrome (major). Methylene blue is a potent MAOI and can cause serious or fatal serotonin syndrome when combined with SSRIs, SNRIs, other MAOIs, or opioids — a boxed/black-box-level warning [Human — documented].
• Discoloration. Causes blue-green urine and skin/tissue discoloration.
• G6PD deficiency. Can trigger hemolysis in people with G6PD deficiency; at high doses it can paradoxically worsen methemoglobinemia.
• Purity uncertainty. The difference between consumer/"pharmaceutical-grade" and industrial-grade methylene blue is not verifiable from the sources here.

Legal status

Methylene blue is a prescription medicine for its approved indication (methemoglobinemia) and is also distributed as a research reagent. Regulatory status is jurisdiction-specific and this page does not assess the legality of any particular use. On the anti-doping axis, methylene blue is not listed as a named prohibited substance on the WADA Prohibited List. Note a separate caveat reported by a secondary source, not independently confirmed here against the primary WADA document: the general WADA M2 (chemical and physical manipulation) method restricts intravenous infusions/injections above 100 mL per 12 h outside a hospital, surgical procedure, or valid TUE — a limit that could in principle apply to high-volume IV MB infusion, not to MB as a substance. No WADA class code (e.g., S0/S2) applies, since methylene blue is not a scheduled/named prohibited substance.

How it compares

Methylene blue is often grouped with peptides and small molecules discussed in a longevity and mitochondrial context — most naturally SS-31 and MOTS-c. The key honesty point: methylene blue is not a peptide, and its human evidence is lopsided — strong for methemoglobinemia, thin for cognition.

Takeaways:

• Different chemistry. Methylene blue is a small-molecule dye; SS-31 and MOTS-c are peptides. They only share a loose "mitochondrial" theme.
• Different evidence. Methylene blue has real regulatory approval — but only for methemoglobinemia, not for cognition or longevity.
• Shared caution. For longevity/cognitive claims, methylene blue's human data is thin (one small single-dose study) and it carries a serious MAOI interaction risk the peptides do not.

Common misconceptions

• "Methylene blue is a peptide / mitochondrial peptide." No. It is a small-molecule synthetic phenothiazine redox dye. It is listed here only because it is discussed alongside peptides.
• "It's an approved nootropic / anti-aging drug." No. Its approval is only for acquired methemoglobinemia (FDA 2016, EMA 2011). Cognitive and anti-aging use is off-label.
• "Human studies prove it boosts memory long-term." Overstated. The main human cognitive study was single-dose, N=26 healthy adults, showing a ~7% acute memory-retrieval improvement — not durable-benefit evidence. The related LMTM Alzheimer's trials failed their primary endpoints.
• "It's basically harmless." No. It is a potent MAOI with a documented serotonin-syndrome risk, causes blue-green discoloration, and can cause hemolysis in G6PD deficiency.
• "Any methylene blue is pharmaceutical-grade." Purity of consumer vs industrial material (heavy-metal contamination) is not verifiable from these sources.